

Programme PAIR Sein 2014-2018
Early stage of breast cancer


- RiboTEM -

Role of ribosome alterations in epithelial-to-mesenchymal transition in breast cancer


Jean-Jacques DIAZ

« Nuclear Domains & Pathologies » Team
Cancer Research Center of Lyon (CRCL)




CRCL CENTRE DE
RECHERCHE EN
CANCÉROLOGIE
DE LYON



Translation contributes to the hallmarks of cancer



Dysregulation of translation in cancer




Specific mRNA translation


Marcel et al, *Oncogene* 2015
 Truitt & Ruggero, *Nat Rev Cancer* 2016
 Tahmasebi et al, *Nat Rev Mol Cell Biol* 2018
 Marcel et al, *Cancers* 2018

Xue & Barna, *Nat Rev Mol Cell Biol* 2012
 Shi & Barna, *Annu Rev Cell Dev Biol* 2015
 Genuth & Barna, *Nat Rev Genetics* 2018
 Dalla Venezia et al, *IJMS* 2019

rRNA methylation modulates translation



Marcel et al, Cancer Cell 2013



Erales et al, PNAS 2017

Belin et al, Plos ONE 2009

Marcel et al, Oncotarget 2013

Marcel et al, Med Sci 2014

Marcel et al, Mol Cell Biol 2015

Marcel et al, Oncogene 2015

Thérizols et al, Book « Epigenetic Cancer Therapy » 2015

Marcel et al, Cancers 2018


Monaco et al, Biomolecules 2018

Catez et al, Bioch Pharmacol 2019

Dalla Venezia et al, IJMS 2019


Wei et al, Mol Cell 2019

Objectives and hypotheses of PAIR Sein program




- ✓ Role of ribosome alterations in early stage of mammary tumorigenesis ?
- ✓ Use of ribosome alterations as biomarkers of prognosis at early diagnosis ?

Part 1 | Alterations of ribosome composition and translation in EMT



- Tumor initiation
- Invasion and migration



Partners

A. Puisieux



CRCL CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON

O. Namy


I2BC

Part 1 | A translational reprogramming occurs in EMT


Ribosome Profiling



Coordinated change in mRNA levels and translation





Change in translation without change in mRNA levels





- Transcription n=599 genes
- Translation n=755 genes

Part 1 | The composition of the translational machinery is changed in EMT

rRNA methylation profiling (RiboMETH-seq)



RiboProteome



Part 2 | Prognostic values of ribosome biogenesis factors in breast cancer diagnosed at early stages

Series 1 : 216 total RNA

(Collab: Jean Christophe Bourdon, Dundee)



Test series

Series 2 : 40 total RNA

(Collab: Gilles Clapisson, Lyon)



Series 6 : 434 tissues (TMA)

(Collab: Isabelle Treilleux, Lyon)

Series 3 : 11 total RNA from healthy donors mastectomy

(Collab: Thierry Dubois, Paris)



Series 4 : 661 total RNA

(The Cancer Genome Atlas)



Validation series

Series 5 : 196 total RNA

(Collab: Fabrice André, Paris)



Series 7 : 1987 tissues (TMA)

(Collab: Fabrice André, Paris)

Partners

I. Treilleux
D. Pérol







F. André



Characteristics of the series

- Women
- Invasive tumors
- No medical history
- No distant metastasis at diagnosis

Part 2 | FBL and NCL are independent markers of poor prognosis in early breast cancer





Variables	HR	P-value	
FBL	intermediate	1.00	
	low	1.83 [1.13 – 2.96]	0.0215*
	high	1.69 [1.02 – 2.80]	
Size	small (< 30mm)	1.00	
	large (≥ 30mm)	2.27 [1.08 – 2.46]	< 0.0001***
Lymph node	no	1.00	
	yes	1.63 [1;52 – 3.40]	0.0201*


Part 2 | Decreased expression of *FBL* contributes to spontaneous tumorigenesis *in vivo*

Cohort of 124 zebrafishes

Spontaneous model of tumorigenesis
(*tp53*^{M214K/M214K}) X *fbl*^{+/-}



Conclusions



✓ Basic research: novel ribosome-associated concepts in early breast cancer tumorigenesis

- **Translational reprogramming** and **alterations of ribosome composition** in EMT
- **Reduction of ribosome biogenesis** contributes in mammary tumorigenesis

✓ Translational/clinical research: ribosome as biomarker

- FBL and NCL are **prognostic markers**

Perspectives

- Role of **ribosome in EMT** (ARC, LNCC)
- Alterations and role of **rRNA methylation in breast cancer** (MARACAS: ARC 2017, PLBio 2019; ACTIMETH: ANR 2019)
- Use of **rRNA methylation as biomarker of EMT** (EMT-Concept: PRT-K 2017)


DEBRIEFING | RiboTEM program

Opportunities

- Initiate a **long-term research program** on ribosome and EMT
- Set aside **strong collaborations with clinicians**
- Build **consortium of about 10 national and international teams** on ribosome/translation in breast cancer

Valorization

- 9 publications
- 1 bioinformatic tool (Ribosome Profiling)
- ≈20 invited presentations



PAIR Sein 2014-2018




Difficulties

- Pursue the program as an **integrated one** (basic and translational research) due to the lack of equivalent funding
 - Separation of research into different sub-projects

Perspectives

- Role of **ribosome in EMT** (ARC, LNCC)
- Alterations and role of **rRNA methylation in breast cancer** (MARACAS: ARC 2017, PLBio 2019; ACTIMETH: ANR 2019)
- Use of **rRNA methylation as biomarker of EMT** (EMT-Concept: PRT-K 2017)



Acknowledgements

“Nuclear domains & Pathologies” Team



Jean-Jacques DIAZ
Virginie MARCEL
Flora NGUYEN VAN LONG
Hermes PARAQINDES
Nathalie PION
Déborah MONCHIET
Valentin SIMIONI
Marjorie MARTIN
Agathe DOLBEAU
Paul ROLLET
Akari SAKU
Xinrui DONG

Philippe BOUVET
Frédéric CATEZ
Nicole DALLA VENEZZIA
Hélène DELAGE
Hichem MERTANI
Fabien MONGELARD
Karine MONIER
Jean-Christophe SAURIN
Anne VINCENT
Mounira CHABALI
Elizabeht GOMEZ CRUZ
Piero LO MONACO
Anthéa HULEUX
Angéline GAUCHEROT

Collaborators

CRCL/Curie
(Lyon, France)

Alain Puisieux
Anne-Pierre Morel

CLB – UBET
(Lyon, France)

David Pérol
Sylvie Chabot
Isabelle Treilleux
Audrey Lardy-Cleaud

CLB – Bioinformatics
G.Thomas platform
(Lyon, France)

Alain Viari
Janice Kielbassa

Université de Lorraine
(Nancy, France)

Iouri Motorine
Virginie Marchand

CLB – Translational
research
(Lyon, France)

Pierre Saintigny
Sandra Ortiz-Cuaran
Marie-Alexandra Albaret

IGDR
(Rennes, France)

Reynald Gillet
Sophie Chat



Université Paris XI
(Paris, France)

Olivier Namy
Laure Bidou
Agnès Baudin-Baulieu

IGR
(Villejuif, France)

Fabrice André
Ibrahim Bouakka

University of Dundee
(Scotland, UK)

JC Bourdon
Susan Bray
Alastair Thompson

EDyP – INSERM/CEA/UGA
(Grenoble, France)

Yohan Couté
Annie Adrait

